Read More Pharma Industry News Avacta Group (AIM: AVCT) closes oversubscribed £10m placing at 9.35% discount as AVA6103 enters clinical dosing Avacta Group (AIM: AVCT) completes an oversubscribed £10m equity placing at 63p ahead of late-2026 AVA6103 Phase 1 data. Read the full analyst breakdown. bySrinathMarch 27, 2026